Found: 3
Select item for more details and to access through your institution.
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m<sup>2</sup> every 21 days in patients with cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 1, p. 136, doi. 10.1007/s10637-012-9815-9
- By:
- Publication type:
- Article
Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally...
- Published in:
- Annals of Internal Medicine, 1996, v. 125, n. 9, p. 723, doi. 10.7326/0003-4819-125-9-199611010-00003
- By:
- Publication type:
- Article
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 11, p. 1400, doi. 10.1002/jcph.942
- By:
- Publication type:
- Article